PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
402.37%
G&A growth less than half of AGEN's 26460.78%. David Dodd would verify if efficiency advantage is structural.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Other expenses change of 100.00% while AGEN maintains costs. Bruce Berkowitz would investigate efficiency.
547.73%
Operating expenses growth while AGEN reduces costs. John Neff would investigate differences.
547.73%
Total costs growth above 1.5x AGEN's 0.15%. Michael Burry would check for inefficiency.
3.95%
Interest expense growth above 1.5x AGEN's 1.81%. Michael Burry would check for over-leverage.
-96.03%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-2633.53%
EBITDA decline while AGEN shows 288.80% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-468.26%
Operating income decline while AGEN shows 258.49% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
6409.86%
Other expenses growth above 1.5x AGEN's 94.60%. Michael Burry would check for concerning trends.
-429.59%
Pre-tax income decline while AGEN shows 27399.86% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-75.15%
Tax expense reduction while AGEN shows 105.99% growth. Joel Greenblatt would examine advantage.
-263.73%
Net income decline while AGEN shows 212.41% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-197.18%
EPS decline while AGEN shows 207.41% growth. Joel Greenblatt would examine position.
-197.18%
Diluted EPS decline while AGEN shows 207.41% growth. Joel Greenblatt would examine position.
22.83%
Share count change of 22.83% while AGEN is stable. Bruce Berkowitz would verify approach.
22.83%
Diluted share change of 22.83% while AGEN is stable. Bruce Berkowitz would verify approach.